Ozempic vs Wegovy vs Zepbound: Which GLP-1 Is Right for You?

Published Jan 28, 2025Updated Sep 30, 2026Last reviewed Jan 28, 2025

11 linked public sourcesEditorial, sourcing, and corrections policy

Ozempic and Wegovy contain semaglutide; Zepbound contains tirzepatide. The most useful comparison starts with the condition being treated, then considers weight-loss results, other health benefits, side effects, and the formulation you can use consistently. A brand's approved use and dose matter as much as the ingredient name.

What is each brand used for?

Brand	Ingredient	Main U.S. treatment uses relevant to adults
Ozempic	Semaglutide	Type 2 diabetes; cardiovascular risk reduction in people with type 2 diabetes and established cardiovascular disease; kidney and cardiovascular risk reduction in people with type 2 diabetes and chronic kidney disease. [1]
Wegovy	Semaglutide	Long-term weight management; cardiovascular risk reduction in eligible adults with established cardiovascular disease and overweight or obesity. Injection also treats eligible adults with MASH and moderate to advanced liver fibrosis without cirrhosis. [2,3]
Zepbound	Tirzepatide	Long-term weight management in eligible adults; moderate to severe obstructive sleep apnea in adults with obesity. [4]
Mounjaro	Tirzepatide	Type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk of cardiovascular events. [5]

The weight-management medicines are used with nutrition and physical activity. Ozempic can reduce weight, but it is not the semaglutide brand approved specifically for weight management. [1,2]

Which produces more weight loss?

In SURMOUNT-5, 751 adults with obesity without type 2 diabetes received weekly tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg, according to the maximum dose they could tolerate. Average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. This was a randomized, open-label comparison. [6]

That result compares those injectable doses. It does not compare every current semaglutide formulation.

STEP UP studied semaglutide 7.2 mg against 2.4 mg and placebo in adults with obesity without diabetes. At 72 weeks, average weight loss was 18.7%, 15.6%, and 3.9%, respectively. Gastrointestinal symptoms and altered skin sensations were more frequent with 7.2 mg. Tirzepatide was not a treatment arm. [7]

A larger average reduction may matter when substantial weight loss is a treatment goal. It still needs to be considered alongside how a medicine fits your health conditions and whether you can continue taking it.

Is Wegovy a pill or an injection?

The current U.S. label includes both. Wegovy injection is weekly; tablets are daily. Adult tablets have a 25 mg maintenance dose after escalation. Take them on an empty stomach in the morning with up to four ounces of water, then wait at least 30 minutes before food, other drinks, or oral medicines. [2]

For adult weight management, weekly injections usually use 2.4 mg; 1.7 mg is another maintenance option. A prescriber may increase to 7.2 mg after at least four weeks tolerating 2.4 mg when additional weight reduction is indicated. The 7.2 mg option is not the maintenance schedule for every Wegovy indication. [2]

Tablets and injections are different formulations. Their milligram numbers are not a conversion chart.

When do other health conditions change the choice?

Established cardiovascular disease

SELECT enrolled 17,604 adults with existing cardiovascular disease and overweight or obesity, without diabetes. Major cardiovascular events occurred in 6.5% receiving semaglutide 2.4 mg and 8.0% receiving placebo over an average 39.8 months of follow-up. That was a 20% relative reduction, or a 1.5 percentage-point absolute difference. [8]

Those findings describe people who already had cardiovascular disease, not everyone seeking weight loss. For adults with type 2 diabetes, both Ozempic and Mounjaro also have cardiovascular indications, with the eligible populations specified in their labels. [1,5]

Type 2 diabetes and chronic kidney disease

Ozempic has a kidney-related indication for this population. In FLOW, 3,533 participants with type 2 diabetes and chronic kidney disease received weekly semaglutide 1 mg or placebo. The primary composite outcome included kidney failure, a substantial decline in kidney function, or kidney-related or cardiovascular death. Its risk was 24% lower with semaglutide over a median 3.4 years. [1,9]

Someone with diabetes and kidney disease therefore needs more than a comparison of pounds lost.

Obstructive sleep apnea

Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. The approval followed studies in people with and without positive airway pressure treatment. Include the sleep clinician in treatment planning rather than stopping prescribed airway treatment when weight begins to fall. [4]

MASH with liver fibrosis

Wegovy injection is approved for adults with noncirrhotic MASH and F2 to F3 fibrosis. The diagnosis and fibrosis stage matter: an elevated liver enzyme or a fatty-liver finding alone does not establish this treatment indication. [3]

Side effects and medical history to discuss

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort can occur with these medicines. Dose escalation gives the care team opportunities to assess tolerability. Report symptoms that interfere with eating or drinking before the next planned increase. [10,11]

Tell the prescriber about pancreatitis, gallbladder problems, severe stomach-emptying problems, kidney disease, and all other medicines. Insulin or sulfonylurea treatment may need adjustment to reduce low-blood-sugar risk. These medicines should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN2. [10,11]

Discuss pregnancy plans before treatment. Semaglutide should be stopped at least two months before a planned pregnancy. [10,11]

How to compare the real cost

Ask for the cost of the exact brand, formulation, and dose being prescribed. A useful estimate includes the medication, required appointments, and any recurring program fees.

Before choosing a plan, confirm:

Which diagnosis and documentation your insurer requires.
Whether the quoted price changes after an introductory period.
Whether dose increases change the medication price.
Who manages side effects, interruptions, and prescription renewals.
What happens if coverage or supply changes.

A price advertised for a starting dose does not tell you the full cost of maintenance. Record the answers in one place so the comparison uses the same time period and services.

Common questions

Can I switch from Ozempic to Wegovy because they contain the same medicine?

A prescriber can plan a switch, but the products have different doses and indications. Do not overlap semaglutide products or use the package strength as a self-directed conversion. [1,2]

Is Zepbound the same as Mounjaro?

They contain the same active ingredient, tirzepatide. Their approved uses and product instructions are not identical. [4,5]

Which should I ask about first?

Start with the problem you want treatment to address: weight, diabetes, cardiovascular disease, kidney disease, sleep apnea, or an established liver diagnosis. Then compare the appropriate options against your medication history, preferred dosing routine, and ongoing cost. Bring that short list to the prescribing visit.

References

Evidence overview for Ozempic vs Wegovy vs Zepbound: Which GLP-1 Is Right for You?